/ANAB
ANAB Stock - AnaptysBio, Inc.
Healthcare|BiotechnologyNASDAQ
$49.08+3.26%
+$1.55 (+3.26%) • Dec 19
90
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+41.4%upside
Target: $69.40
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ANAB
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$48.59 – $49.57
TARGET (TP)$69.40
STOP LOSS$45.15
RISK/REWARD1:5.2
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.29
52W High$49.90
52W Low$12.21
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $91.28M | $17.16M | $10.29M | $63.17M | $75.00M |
| Gross Profit | $-72,560,000 | $-115,126,000 | $-78,511,000 | $-35,321,000 | $-5,025,000 |
| Gross Margin | -79.5% | -671.0% | -763.2% | -55.9% | -6.7% |
| Operating Income | $-114,949,000 | $-164,411,000 | $-115,154,000 | $-56,814,000 | $-23,879,000 |
| Net Income | $-145,231,000 | $-163,619,000 | $-128,723,999 | $-57,796,000 | $-19,931,000 |
| Net Margin | -159.1% | -953.7% | -1251.3% | -91.5% | -26.6% |
| EPS | $-5.12 | $-6.08 | $-4.57 | $-2.11 | $-0.73 |
Company Overview
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
11
73%
Hold / Neutral
4
27%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
11 Bullish4 Neutral/Bearish
Price Targets
$46
Average Target
↓ 6.8% Downside
Now
$19
Low
$46
Average
$80
High
Based on 17 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 13th 2025 | Barclays | Initiation | Overweight | $78 |
| June 4th 2025 | H.C. Wainwright | Upgrade | Buy | $38 |
| February 4th 2025 | Wolfe Research | Initiation | Outperform | $25 |
| December 11th 2024 | H.C. Wainwright | Downgrade | Neutral | $19← $52 |
| December 2nd 2024 | BTIG Research | Downgrade | Neutral | - |
| July 22nd 2024 | H.C. Wainwright | Initiation | Buy | $55 |
| July 19th 2024 | JP Morgan | Upgrade | Overweight | $69← $29 |
| April 16th 2024 | Leerink Partners | Initiation | Outperform | $47 |
| April 11th 2024 | Wells Fargo | Initiation | Overweight | $56 |
| March 12th 2024 | Wedbush | Upgrade | Outperform | $34← $20 |
| February 26th 2024 | BTIG Research | Initiation | Buy | $55 |
| February 21st 2024 | Stifel | Initiation | Buy | $50 |
| February 16th 2024 | Piper Sandler | Initiation | Overweight | $80 |
| May 22nd 2023 | JP Morgan | Upgrade | Neutral | $30← $31 |
| May 18th 2023 | TD Cowen | Initiation | Outperform | - |
Earnings History & Surprises
ANABBeat Rate
56%
Last 18 quarters
Avg Surprise
-1.9%
EPS vs Estimate
Beats / Misses
10/8
Last 12 quarters
Latest EPS
$0.52
Q4 2025
EPS Surprise History
Q1 24
+8.6%
$-1.59vs$-1.74
Q2 24
-6.5%
$-1.64vs$-1.54
Q3 24
-42.5%
$-1.71vs$-1.20
Q4 24
+33.7%
$-1.14vs$-1.72
Q1 25
+55.3%
$-0.72vs$-1.61
Q2 25
+1.5%
$-1.28vs$-1.30
Q3 25
+10.7%
$-1.34vs$-1.50
Q4 25
+149.1%
$0.52vs$-1.06
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $0.89 | — | — | — |
Q4 2025 | Nov 4, 2025 | $-1.06 | $0.52 | +149.1% | ✓ BEAT |
Q3 2025 | Aug 6, 2025 | $-1.50 | $-1.34 | +10.7% | ✓ BEAT |
Q2 2025 | May 5, 2025 | $-1.30 | $-1.28 | +1.5% | ✓ BEAT |
Q1 2025 | Feb 27, 2025 | $-1.61 | $-0.72 | +55.3% | ✓ BEAT |
Q4 2024 | Nov 5, 2024 | $-1.72 | $-1.14 | +33.7% | ✓ BEAT |
Q3 2024 | Aug 5, 2024 | $-1.20 | $-1.71 | -42.5% | ✗ MISS |
Q2 2024 | May 9, 2024 | $-1.54 | $-1.64 | -6.5% | ✗ MISS |
Q1 2024 | Mar 11, 2024 | $-1.74 | $-1.59 | +8.6% | ✓ BEAT |
Q4 2023 | Nov 2, 2023 | $-1.72 | $-1.41 | +18.0% | ✓ BEAT |
Q3 2023 | Aug 7, 2023 | $-1.65 | $-1.50 | +9.1% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-1.04 | $-1.58 | -51.9% | ✗ MISS |
Q1 2023 | Mar 1, 2023 | $-0.92 | $-0.93 | -1.1% | ✗ MISS |
Q4 2022 | Nov 8, 2022 | $-0.47 | $-1.18 | -151.1% | ✗ MISS |
Q3 2022 | Aug 8, 2022 | $-0.95 | $-1.15 | -21.1% | ✗ MISS |
Q2 2022 | May 4, 2022 | $-0.87 | $-1.31 | -50.6% | ✗ MISS |
Q1 2022 | Mar 7, 2022 | $2.28 | $-1.13 | -149.6% | ✗ MISS |
Q4 2021 | Nov 4, 2021 | $-0.74 | $-0.24 | +67.6% | ✓ BEAT |
Q3 2021 | Aug 9, 2021 | $-0.15 | $-0.02 | +86.7% | ✓ BEAT |
Latest News
Barclays Maintains Overweight on AnaptysBio, Lowers Price Target to $55
➖ NeutralBenzinga•Dec 17, 2025, 05:32 PM•Also:
Stifel Maintains Buy on AnaptysBio, Lowers Price Target to $56
➖ NeutralBenzinga•Dec 11, 2025, 01:17 PM•Also:
AnaptysBio And Tesaro/GSK File Competing Delaware Lawsuits Alleging Breaches Of Their Collaboration And License Agreement
📉 NegativeBenzinga•Nov 26, 2025, 09:05 PM
Wedbush Reiterates Outperform on AnaptysBio, Maintains $50 Price Target
📈 PositiveBenzinga•Nov 24, 2025, 01:23 PM
HC Wainwright & Co. Maintains Buy on AnaptysBio, Lowers Price Target to $51
📈 PositiveBenzinga•Nov 24, 2025, 12:25 PM
ANAB stock has given up its prior loss. AnaptysBio shares were trading lower.
➖ NeutralBenzinga•Nov 21, 2025, 06:41 PM
AnaptysBio shares are trading lower. The company announced a $100 million stock repurchase plan.
➖ NeutralBenzinga•Nov 21, 2025, 02:01 PM
AnaptysBio drops after litigation with GSK unit risks cancer therapy deal
📉 NegativeSeeking Alpha•Nov 21, 2025, 12:10 PM•Also:
Anaptys Board Approves $100M Stock Repurchase Plan In Addition To $6.4M Remaining Under Prior $75M Program
📈 PositiveBenzinga•Nov 21, 2025, 09:03 AM
GSK Subsidiary Tesaro Initiates Litigation Against AnaptysBio Over Material Breach Of Jemperli License Agreement
📉 NegativeBenzinga•Nov 21, 2025, 08:55 AM•Also:
Barclays Maintains Overweight on AnaptysBio, Lowers Price Target to $70
➖ NeutralBenzinga•Nov 11, 2025, 02:55 PM•Also:
HC Wainwright & Co. Maintains Buy on AnaptysBio, Lowers Price Target to $52
➖ NeutralBenzinga•Nov 11, 2025, 11:24 AM
Truist Securities Maintains Hold on AnaptysBio, Raises Price Target to $36
➖ NeutralBenzinga•Nov 10, 2025, 04:11 PM
Trading Halt: Halt status updated at 9:45:00 AM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Nov 10, 2025, 02:45 PM
Anaptys Phase 2 Trial Of Rosnilimab Did Not Meet Primary Or Secondary Endpoints At Week 12 In Moderate-to-Severe Ulcerative Colitis; Trial To Be Discontinued
📉 NegativeBenzinga•Nov 10, 2025, 02:03 PM
Trading Halt: Halted at 8:55:00 a.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Nov 10, 2025, 01:55 PM
Guggenheim Maintains Buy on AnaptysBio, Raises Price Target to $100
📈 PositiveBenzinga•Nov 5, 2025, 03:07 PM
Wells Fargo Maintains Overweight on AnaptysBio, Raises Price Target to $81
📈 PositiveBenzinga•Nov 5, 2025, 02:56 PM
AnaptysBio shares are trading higher after the company reported better-than-expected Q3 financial results.
📈 PositiveBenzinga•Nov 4, 2025, 09:55 PM
AnaptysBio Q3 EPS $0.52 Beats $(1.42) Estimate, Sales $76.320M Beat $15.811M Estimate
📈 PositiveBenzinga•Nov 4, 2025, 09:38 PM
Frequently Asked Questions about ANAB
What is ANAB's current stock price?
AnaptysBio, Inc. (ANAB) is currently trading at $49.08 per share. The stock has moved +3.26% today.
What is the analyst price target for ANAB?
The average analyst price target for ANAB is $69.40, based on 1 analyst.
What sector is AnaptysBio, Inc. in?
AnaptysBio, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ANAB's market cap?
AnaptysBio, Inc. has a market capitalization of $1.36 billion, making it a small-cap company.
Does ANAB pay dividends?
No, AnaptysBio, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBBOT
BridgeBio Oncology Therapeutics Inc.
$12.52
Mkt Cap: $1.0B
DNTH
Dianthus Therapeutics, Inc.
$42.44
Mkt Cap: $1.5B
KOD
Kodiak Sciences Inc.
$26.00
Mkt Cap: $1.4B
MNMD
Mind Medicine (MindMed) Inc.
$12.70
Mkt Cap: $1.0B
NRIX
Nurix Therapeutics, Inc.
$18.52
Mkt Cap: $1.4B
OCS
Oculis Holding AG
$21.25
Mkt Cap: $1.1B
PHAT
Phathom Pharmaceuticals, Inc.
$17.53
Mkt Cap: $1.2B
TSHA
Taysha Gene Therapies, Inc.
$5.49
Mkt Cap: $1.6B
URGN
UroGen Pharma Ltd.
$22.80
Mkt Cap: $1.1B
XNCR
Xencor, Inc.
$15.55
Mkt Cap: $1.1B
Explore stocks similar to ANAB for comparison